Polysaccharides (e.g., Cellulose, Etc.) Patents (Class 424/488)
-
Patent number: 8642088Abstract: The invention provides a composition comprising a matrix of chitosan and a tannin wherein the chitosan is electrostatically bonded to the tannin to form a chitosan-tannin composite material. The chitosan can be partially or fully deacetylated, and the tannin can be a monomeric or an oligomeric proanthocyanidin or a hydrolysable tannin. The chitosan-tannin composite material can be a nanoparticle, a hydrogel film, a bio-foam, or a biogel, or the chitosan-tannin composite material can coat a liposome. The composite materials can be used for drug delivery, for antibacterial and/or antifungal applications, for tissue engineering applications, for wound healing applications, or they can be used as adjuvants for vaccination, including oral vaccinations. The invention also provides methods of preparing the composite materials and their various forms.Type: GrantFiled: September 3, 2010Date of Patent: February 4, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Jess Dreher Reed, Christian Gerald Krueger, Sergio Madrigal-Carballo
-
Patent number: 8632813Abstract: Compositions and methods for the treatment of vasospasm are provided comprising applying an amount of a semi-solid vasoactive prostaglandin composition to the affected tissue. Also provided are methods of improving microcirculation in a replanted body part.Type: GrantFiled: October 19, 2007Date of Patent: January 21, 2014Assignee: Nexmed (Holdings), Inc.Inventors: Tian Wen, Liu Liu, Mingqi Lu, Jieshan Bai, Y. Joseph Mo
-
Patent number: 8632805Abstract: The present invention includes a controlled-release composition having a matrix. The matrix contains a pharmaceutically effective amount of an active agent or a pharmaceutically acceptable salt, solvate, ester, and/or prodrug thereof, an ionic non-gelling matrix polymer, and a pH modifier. The ionic non-gelling matrix polymer is practically insoluble and unswellable at a first aqueous fluid pH and is soluble at a second aqueous fluid pH. The pH modifier is present in an amount to control the release of the active agent from the composition. The controlled-release composition is substantially free of a gelling or swellable excipient. The present invention also provides methods of making and using the controlled-release compositions.Type: GrantFiled: June 20, 2008Date of Patent: January 21, 2014Assignee: Mutual Pharmaceutical Company, Inc.Inventors: Gandha V. Naringrekar, Kristin A. Arnold, David Erkoboni
-
Patent number: 8617317Abstract: Renewable, non-volatile cleaning compositions incorporating ethyl ester solvents are disclosed. Preferred compositions employ non-volatile C8-16 ethyl ester solvents. All-purpose cleaning compositions incorporating the non-volatile C8-16 ethyl ester solvents, further include an alkyl polyglycoside surfactant, an alcohol ethoxylate surfactant, and water. Preferably the compositions are free of anionic, cationic and amphoteric surfactants and/or co-solvents. The invention also discloses methods employing the non-volatile solvent all-purpose cleaning compositions.Type: GrantFiled: July 31, 2012Date of Patent: December 31, 2013Assignee: Ecolab USA Inc.Inventor: Mark Dennis Levitt
-
Patent number: 8617604Abstract: Pharmaceutical compositions of a low-solubility drug and lower alkanoate-, phthalate- and trimellitate esters of hydroxypropyl methyl cellulose and lower alkanoate- and succinate esters of cellulose and methyl cellulose are disclosed that provide enhanced concentrations of the drug in a use environment.Type: GrantFiled: January 23, 2006Date of Patent: December 31, 2013Assignee: Bend Research, Inc.Inventors: Walter Christian Babcock, Dwayne Thomas Friesen, David Kenneth Lyon, Warren Kenyon Miller, Daniel Tod Smithey
-
Publication number: 20130337044Abstract: The invention relates to a pharmaceutical composition for the modulation of effector T cell responses made of one or more preparations and comprising a therapeutically effective dose of at least one recombinant human C3-derivative and of at least one antigen or allergen.Type: ApplicationFiled: June 14, 2013Publication date: December 19, 2013Inventors: Reinhard Bredehorst, Thomas Grunwald, Markus Ollert, Carsten Schmidt-Weber, Edzard Spillner
-
Patent number: 8586078Abstract: Oil-in-water emulsion gels and medical articles containing an omega-3 oil are disclosed. Also disclosed are methods of preparing and using such emulsion gels and medical articles.Type: GrantFiled: December 5, 2006Date of Patent: November 19, 2013Assignee: RBA Pharma Inc.Inventors: Marie-Pierre Faure, Kirill Shingel
-
Patent number: 8586089Abstract: Improved compositions for tissue augmentation are provided. These compositions comprise an amount of crosslinked material sufficient to provide a melt temperature (Tm) greater than 37C, wherein microparticles can be substantially uniformly dispersed and maintained at ambient room temperature as well as body temperature. Said compositions also provide high shear moduli, sufficient to effectively deliver microparticles into dense tissue and narrow intersticial spaces without significant disruption to the homogeneous distribution of microparticles within the solution. The provided compositions can be stored and shipped at room temperature without significant detriment to the material composition. Additional embodiments include a system for delivery of tissue augmentation materials and methods of manufacture thereof.Type: GrantFiled: January 3, 2009Date of Patent: November 19, 2013Inventor: Russell J. Anderson
-
Publication number: 20130302420Abstract: A biodegradable drug implant includes a PLG matrix and a non-steroid anti inflammation drug, for example diclofenac sodium. The implant is inserted into the eye in the anterior chamber, for example in the ciliary sulcus, following eye surgery. A method for treating and or preventing inflammation of the eye following eye surgery includes placing the implant in the anterior portion of the eye.Type: ApplicationFiled: May 14, 2012Publication date: November 14, 2013Inventors: Barry L. Bowyer, James P. Gills
-
Patent number: 8580830Abstract: Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the dosage forms for the treatment of various medical conditions are provided.Type: GrantFiled: October 2, 2007Date of Patent: November 12, 2013Assignees: Labtec GmbH, APR Applied Pharma Research S.A.Inventors: Christian Leichs, Armin Breitenbach, Ingo Lehrke, Paolo Galfetti
-
Patent number: 8568778Abstract: The invention relates to an oral, multiparticulate form of administration, comprising pellets in the size ranging from 50 to 2500 $g(m)m which are substantially constituted of a) an inner matrix layer containing nanoparticles that contain a nucleic acid active ingredient and being embedded in a matrix of a polymer having a mucoadhesive effect, and b) an outer film coating, substantially consisting of an anionic polymer or copolymer that is optionally formulated with pharmaceutically conventional adjuvants, especially emollients.Type: GrantFiled: November 5, 2005Date of Patent: October 29, 2013Assignee: Evonik Röhm GmbHInventors: Rosario Lizio, Hans-Ulrich Petereit, Dave Trupti, Michael Gottschalk
-
Patent number: 8563039Abstract: New biomaterials consisting of a combination of sulphated hyaluronic acid and gellan (as well as gellan that has not been associated with other polymers), to be used as a highly effective barrier to prevent post-surgical adhesions in abdominal, pelvic and, above all, spine surgery.Type: GrantFiled: October 3, 2005Date of Patent: October 22, 2013Assignee: Anika Therapeutics S.R.L.Inventors: Davide Bellini, Cristina Longinotti, Vittorio Crescenzi, Anna Taglienti
-
Patent number: 8563040Abstract: Compositions are provided which stimulate bone growth. Also provided are methods for utilizing the compositions for filling in bone defects, promoting rapid fusion of bone fractures, grafts, and bone-prostheses, and promoting strengthening of osteoporotic bones.Type: GrantFiled: October 19, 2009Date of Patent: October 22, 2013Assignee: Marfly 2, LPInventor: J. Alexander Marchosky
-
Publication number: 20130273162Abstract: A control release and abuse-resistant opiate drug delivery oral wafer or edible oral film dosage to treat pain and substance abuse is provided. The drug delivery oral wafer or edible oral film dosage includes a controlled release layer containing enteric-release beads dispersed in a polymer matrix. The enteric-release beads are formed from a therapeutic amount of an opioid agonist and/or pharmaceutically acceptable salt thereof and a sub-therapuetic amount of opioid antagonist and/or pharmaceutically acceptable salt thereof coated or encapsulated in an enteric-release polymer. The controlled release polymer matrix dissolves or disintegrates following administration or consumption of the oral wafer or edible oral film, releasing the enteric-release beads to be swallowed, with subsequent absorption of the active ingredients within the patient's intestines.Type: ApplicationFiled: April 12, 2012Publication date: October 17, 2013Inventor: Michael Hsin Chwen LI
-
Patent number: 8557286Abstract: The invention relates to a method for producing pharmaceutical forms or preliminary stages thereof by means of extrusion. The pharmaceutical form has a matrix which the active agent is contained essentially, and whose essential characteristics are determined by the extrusion process and which comprises a polysaccharide and/or derivative thereof and/or a complex thereof and/or any mixture of the aforementioned substances with other substances and/or saccharides and/or derivatives thereof as an essential constituent, and at least one pharmaceutically active substance.Type: GrantFiled: April 20, 2000Date of Patent: October 15, 2013Assignee: EuroCeltique, S.A.Inventors: Hubert Rein, Klaus-Jurgen Steffens
-
Patent number: 8557275Abstract: Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA either alone or in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.Type: GrantFiled: April 4, 2011Date of Patent: October 15, 2013Assignee: U.S. Nutraceuticals, LLCInventors: John A. Minatelli, W. Stephen Hill, Rudi E. Moerck
-
Patent number: 8551502Abstract: Hydrogel-bacterial cellulose nano-composite materials are created using a hydrogel and never dried bacterial cellulose fibers. Such materials are suitable for a broad range of soft tissue replacement applications. In addition controlled release of bioactive agents properties can be designed into medical devices fabricated from such composite materials.Type: GrantFiled: October 31, 2007Date of Patent: October 8, 2013Assignee: Axcelon Biopolymers CorporationInventors: Wan-Kei Wan, Leonardo Millon
-
Publication number: 20130259937Abstract: Chewable sustained release compositions and their methods of production are provided. The sustained release compositions contain amphipathic lipids and matrix-forming polymers, which are used to encapsulate various drugs and active ingredients. The chewable sustained release compositions can maintain their sustained release properties even after being fragmented into a plurality of pieces.Type: ApplicationFiled: May 31, 2013Publication date: October 3, 2013Inventors: Scott A. Howard, Troy Purvis
-
Patent number: 8545886Abstract: The invention is directed to a Pharmaceutical extended release system, particularly for oral administration, of a pH-dependent water-soluble active substance, comprising or essentially consisting of a) flibanserin or a pharmaceutically acceptable derivative thereof as active substance; b) one or more pharmaceutically acceptable pH-dependent polymers; c) one or more pharmaceutically acceptable pH-independent polymers; d) one or more pharmaceutically acceptable acids; and e) optionally one or more additives. The present invention provides a release profile of flibanserin which is independent on the pH in the gastrointestinal tract when administered orally resulting in a significantly improved bioavailability.Type: GrantFiled: August 13, 2007Date of Patent: October 1, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Wolfram Eisenreich, Thomas Friedl
-
Patent number: 8545861Abstract: A fibrous web, in particular tissue web treated with a lotion composition based on an O/W emulsion comprising: (A) at least one oil; (B) an (O/W) emulsifier or (O/W) emulsifier combination; and (C) 6 to 30 weight % of water; wherein the weight % values relate to the total weight of the lotion composition. Since in the above lotion composition the external phase is aqueous, a web treated therewith can easily be wet by water and does not float on the water if it is to be disposed in a toilet.Type: GrantFiled: December 22, 2004Date of Patent: October 1, 2013Assignee: SCA Hygiene Products GmbHInventors: Guido Baumöller, Rolf Kawa, Stephan Eichhorn, Roland Sporer
-
Patent number: 8536231Abstract: The present invention provides methods and pharmaceutical formulations for treating diabetic foot ulcers.Type: GrantFiled: May 9, 2012Date of Patent: September 17, 2013Inventors: Kathleen E. Rodgers, Gere S. diZerega
-
Patent number: 8529951Abstract: Disclosed are elastogenic cues that can be utilized to encourage growth and development of elastin-containing cellular constructs. The elastogenic cues include hyaluronan fragments and oligomers, optionally in conjunction with growth factors and/or a source of copper ions. The elastogenic cues can up-regulate elastin matrix synthesis and by vascular smooth muscle cells. In addition to encouraging synthesis of elastin in a cellular matrix and organization into elastic fibers, the elastogenic cues can also stabilize the formed ECM matrix through suppression of elastin-laminin receptor (ELR). In addition, the elastogenic cues can inhibit cell hyper-proliferation (e.g., hyperplasia) common in inflammatory vascular disease.Type: GrantFiled: February 20, 2008Date of Patent: September 10, 2013Inventors: Anand Ramamurthi, Chandrasekhar Kothapalli, Binata Joddar
-
Patent number: 8524271Abstract: A skin wound dressing is disclosed. The skin wound dressing comprises Tremella polysaccharide and alginate and is used to cover on a skin wound to accelerate wound healing. The Tremella polysaccharide is isolated from a hot water extract of Tremella fuciformis. The skin wound dressing is a Tremella polysaccharide composite fiber, a Tremella polysaccharide sponge or a Tremella polysaccharide hydrogel.Type: GrantFiled: July 11, 2011Date of Patent: September 3, 2013Assignee: Agricultural Research InstituteInventor: Shu-Hui Yang
-
Patent number: 8524759Abstract: An improved phenylbutazone carrier composition provides increased palatability to horses. Additionally, the composition improves the bioavailability of the phenylbutazone and thus increases the horse's blood plasma levels of the medicine for the same effective dosage of the medicine.Type: GrantFiled: July 9, 2012Date of Patent: September 3, 2013Inventor: Douglas J. Gordon
-
Patent number: 8518394Abstract: The invention describes the manufacture and use of secretory cell containing bead structures that are coated with agarose. The beads, which are preferably 4 mm-12 mm in diameter, and which preferably contain islets, are made of a particular agarose, i.eagarose which has a sulfate content of less than 0.2 wt % but greater than zero, a pyruvate content of 0-0.1 wt %, and a Kjeldahl nitrogen content of 0-0.04 wt %. The gels found from the agarose exhibit a gel strength of at least 1200 g/cm2 (1.0 wt % concentration), substantial absence of DNA binding in 0.07 M or less tris acetate buffer, and an EEO at 1.0 wt % agarose concentration of 0.05 or less.Type: GrantFiled: September 14, 2006Date of Patent: August 27, 2013Assignee: The Rogosin InstituteInventors: Lawrence Gazda, Barry Smith
-
Patent number: 8512751Abstract: Pharmaceutical compositions are provided for the pharmacological treatment of breathing disorders and, more specifically, to compositions containing agents having serotonin receptor modulating activity for the alleviation of sleep apnea (central and obstructive) and other sleep-related breathing disorders wherein the active ingredients are released such as to extend effective blood plasma concentrations across the period of sleep.Type: GrantFiled: December 20, 2005Date of Patent: August 20, 2013Assignee: Collegium Pharmaceutical, Inc.Inventors: Roman V. Rariy, Michael Heffernan
-
Patent number: 8512752Abstract: Crosslinked derivatives of polycarboxylated polysaccharides are described, wherein at least one of the polysaccharide chains consists of hyaluronic acid or a derivative thereof, crosslinked by means of reactions of the “click chemistry” type and their use in the field of viscosupplementation, plastic surgery, oncologic and reconstructive surgery and also as matrices for controlled release systems of biologically and/or pharmacologically active molecules and/or macromolecules.Type: GrantFiled: September 5, 2007Date of Patent: August 20, 2013Assignee: Fidia Farmaceutici S.p.A.Inventors: Di Meo Chiara, Devis Galesso, Ada Mascolo, Fabiana Crescenzi, Alberta Crescenzi, Flavia Crescenzi, Fulvia Crescenzi, Laura Crescenzi, Vittoria Crescenzi
-
Patent number: 8506983Abstract: Described are bone generation matrixes having an admixture of demineralized bone matrix (DBM) particles and/or bone chips in combination with at least one binding agent selected from the group consisting of alginate, lectin, pectin, gellan gum, starch, collagen and combinations thereof in an aqueous solvent, wherein the DBM particles and/or bone chips are present in an amount of at least 65% by dry weight and the ratio of the aqueous solvent to the dry weight of the DBM particles/bone chips and at least one binding agent is between about 1:1 to about 1:6.Type: GrantFiled: June 18, 2010Date of Patent: August 13, 2013Assignee: Warsaw Orthopedic, Inc.Inventors: Suneeth Elizabeth Mohan, Daniel Andrew Shimko
-
Patent number: 8507629Abstract: A production method of the present invention is a production method of an organic polymer containing two or more organic ring structures and a chain structure threading through the organic ring structures. This method includes a polymerization step of forming the organic polymer, in which the organic ring structures, which are restricted from moving, are disposed at each of a particular constitutional unit, by polymerizing at least one type of monomers each of which has no ionic functional group that releases a metal ion. The above at least one type of monomers include a monomer (M) containing the organic ring structure and a chain component threading through the organic ring structure.Type: GrantFiled: December 6, 2007Date of Patent: August 13, 2013Assignee: Panasonic CorporationInventors: Takayuki Takeuchi, Norihisa Mino, Nobuaki Kambe, Jun Terao
-
Publication number: 20130202705Abstract: This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing a high water-soluble, high dose drug. The dosage form has alcohol resistance and may also have crush resistance.Type: ApplicationFiled: May 9, 2011Publication date: August 8, 2013Applicant: Cima Labs Inc.Inventor: Ehab Hamed
-
Publication number: 20130202691Abstract: A controlled-release oral pharmaceutical composition of at least an active agent, including: a) a lipophilic matrix consisting of lipophilic compounds and/or amphiphilic compounds; and b) an hydrophilic matrix, wherein the hydrophilic matrix includes at least an indigestible polysaccharide, the active ingredient being dispersed in the lipophilic and/or the hydrophilic matrix. The present invention also relates to a process for the preparation of such a pharmaceutical composition.Type: ApplicationFiled: October 28, 2011Publication date: August 8, 2013Applicant: ROQUETTE FRERESInventors: Olaf Haeusler, Marie-Helene Degrave, Daniel Wils, Stefanie Krenzlin, Juergen Siepmann
-
Publication number: 20130195971Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.Type: ApplicationFiled: January 23, 2013Publication date: August 1, 2013Applicants: Array BioPharma, Inc., AstraZeneca ABInventors: AstraZeneca AB, Array BioPharma, Inc.
-
Publication number: 20130189333Abstract: An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, cellulosic fibers embedded in the mouth-stable polymer matrix, and an additive dispersed in the mouth-stable polymer matrix. The oral product is adapted to release the additive from the body when the body is received within the oral cavity and exposed to saliva.Type: ApplicationFiled: January 18, 2013Publication date: July 25, 2013Applicant: ALTRIA CLIENT SERVICES INC.Inventor: Altria Client Services Inc.
-
Patent number: 8481071Abstract: A composition is provided, wherein the composition comprises a water-swellable, water-insoluble polymer, a blend of a hydrophilic polymer with a complementary oligomer capable of hydrogen or electrostatic bonding to the hydrophilic polymer. The composition also includes a backing member. Active ingredients, such as a whitening agent, may be included. The composition finds utility as an oral dressing, for example, a tooth whitening composition that is applied to the teeth in need of whitening. The composition can be designed to be removed when the degree of whitening has been achieved or left in place and allowed to erode entirely. In certain embodiments, the composition is translucent. Methods for preparing and using the compositions are also disclosed.Type: GrantFiled: May 29, 2012Date of Patent: July 9, 2013Assignee: Corium International, Inc.Inventors: Parminder Singh, Adrian Faasse, Gary W. Cleary, Sri Mudumba, Mikhail M. Feldstein, Danir F. Bairamov
-
Patent number: 8481072Abstract: Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found with krill oil and/or marine oil in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.Type: GrantFiled: July 21, 2010Date of Patent: July 9, 2013Assignee: U.S. Nutraceuticals, LLCInventors: John A. Minatelli, W. Stephen Hill, Swati Sebastian Thomas, Lingan Rajendran, Rudi E. Moerck
-
Patent number: 8481081Abstract: A composition comprises a solid dispersion comprising a low-solubility drug and at least one polymer. At least a major portion of the drug in the dispersion is amorphous. The polymer has a glass transition temperature of at least 100° C. measured at a relative humidity of fifty percent. Another aspect of the invention comprises the same composition except that the dispersion has a glass transition temperature of at least 50° C. at a relative humidity of fifty percent. In another aspect of the invention, a composition comprises a solid dispersion comprising a low-solubility drug and a stabilizing polymer. At least a major portion of the drug in the dispersion is amorphous. The composition also includes a concentration-enhancing polymer that increases the concentration of the drug in a use environment. The stabilizing polymer has a glass transition temperature that is greater than the glass transition temperature of the concentration-enhancing polymer at a relative humidity of 50%.Type: GrantFiled: June 10, 2003Date of Patent: July 9, 2013Assignee: Bend Research, Inc.Inventors: Walter C. Babcock, Dwayne T. Friesen, James A. S. Nightingale, Ravi M. Shanker
-
Publication number: 20130171256Abstract: This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing venlafaxine or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance.Type: ApplicationFiled: May 9, 2011Publication date: July 4, 2013Applicant: CIMA LABS Inc.Inventor: Ehab Hamed
-
Publication number: 20130164377Abstract: Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.Type: ApplicationFiled: November 28, 2012Publication date: June 27, 2013Applicant: Depomed, Inc.Inventor: Depomed, Inc.
-
Patent number: 8470370Abstract: The present invention provides stable, self-assembling, biocompatible and biodegradable hydrogel formulations, into which one or more compounds may be incorporated allowing for delayed release or controlled release of the incorporated compounds as the hydrogel is degraded in the body.Type: GrantFiled: November 28, 2012Date of Patent: June 25, 2013Assignees: Aegis Therapeutics, LLC, The UAB Research FoundationInventors: Edward T. Maggio, Elis Meezan, Dennis J. Pillion, Sarah L. Morgan, Joe Baggott
-
Patent number: 8470369Abstract: Bone paste compositions are described, which promote bone healing and remodeling by stimulating bone marrow elements using a combination of hemopoietic agents, angiogenic agents and a bone molecular signaling material.Type: GrantFiled: March 10, 2009Date of Patent: June 25, 2013Assignee: Marfly 2, L.PInventor: J. Alexander Marchosky
-
Patent number: 8460704Abstract: The invention relates to an extended release pharmaceutical composition comprising nevirapine.Type: GrantFiled: June 4, 2008Date of Patent: June 11, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Michael L. Cappola, Svetlana Sienkiewicz, Glenn Charles Snow, Feng-Jing Chen
-
Patent number: 8455459Abstract: Methods for applying injectable fillers are provided. In some embodiments, the methods can extend effectiveness of the injectable filler. In some embodiments, the methods can provide for an elevated level of effectiveness of the injectable filler. In some embodiments, the methods can prolong the effectiveness of the injectable filler.Type: GrantFiled: August 1, 2008Date of Patent: June 4, 2013Assignee: Medicis Pharmaceutical CorporationInventors: Mitchell S. Wortzman, Rhoda Narins, Xiaoming Lin
-
Patent number: 8455464Abstract: A composition for the treatment of adhesions that are formed as a result of an inflammatory response comprising an aqueous formulation containing the polysaccharide dextrin in an effective amount. The invention also discloses a method of treating adhesions that are formed as a result of an inflammatory response.Type: GrantFiled: January 19, 2001Date of Patent: June 4, 2013Assignee: Innovata LimitedInventor: Susan Conroy
-
Patent number: 8455465Abstract: An injectable aqueous composition of hyaluronic acid or one of the salts thereof, one or more polyol(s) and lidocaine is used for cosmetic purposes or for therapeutic purposes. It has improved viscoelastic rheological properties and long in vivo persistence. The polyol is chosen, for example, from glycerol, sorbitol, propylene glycol, mannitol, erythritol, xylitol, maltitol and lactitol. The particular properties are obtained by heat sterilizing the mixture.Type: GrantFiled: November 4, 2009Date of Patent: June 4, 2013Assignee: Anteis S.A.Inventor: Samuel Gavard Molliard
-
Patent number: 8455001Abstract: The invention provides a cellulose derivative having a repeating unit of the formula below, a composition including the cellulose derivative and a phospholipid, a method for production thereof, and an adhesion barrier including the cellulose derivative or the composition. In the formula, R1, R2, and R3 are —H, —CH2—COOH, —CH2—COOX, or —CH2CO-phosphatidylethanolamine, and X is an alkali metal or an alkali earth metal. The degree of substitution of —CH2—COOH and —CH2—COOX is 0.3 to 2.0 in total, and the degree of substitution of —CH2CO-phosphatidylethanolamine is 0.001 to 0.05.Type: GrantFiled: February 6, 2008Date of Patent: June 4, 2013Assignee: Teijin LimitedInventors: Masaya Ito, Hiroaki Kaneko, Yukako Fukuhira, Nobuyuki Endo
-
Patent number: 8450260Abstract: A structured aqueous detergent composition comprising modified cellulose and surfactant characterized in that the composition comprises: a) 0.2 to 10 wt %, preferably 0.4 to 7 wt %, anionic surfactant or zwitterionic surfactant or mixtures thereof, b) 0.5 to 5 wt %, preferably 1 to 2 wt %, dispersed modified cellulose biopolymer, wherein the modification consists of the cellulose having its C6 primary alcohols oxidized to carboxyl moieties (acid/COOH—) on 10 to 70% of the glucose units and substantially all the remainder of the C6 positions occupied by unmodified primary alcohols, c) 0 to 10 wt % non-surfactant electrolyte; d) 0 to 15 wt % other conventional detergent composition additives e) balance water. The invention also provides a method to manufacture the composition.Type: GrantFiled: December 24, 2009Date of Patent: May 28, 2013Assignee: Conopco, Inc.Inventors: Robert John Crawford, Janet Lesley Scott, Giovanni Francesco Unali
-
Patent number: 8450475Abstract: Disclosed herein are soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.Type: GrantFiled: February 26, 2009Date of Patent: May 28, 2013Assignee: Allergan, Inc.Inventor: Pierre F. Lebreton
-
Publication number: 20130129827Abstract: The present invention relates to extended release pharmaceutical compositions of paliperidone and process of preparation thereof.Type: ApplicationFiled: October 18, 2010Publication date: May 23, 2013Applicant: RANBAXY LABORATORIES LIMITEDInventors: Kumaravel Vivek, Rajan Kumar Verma, Romi Barat Singh
-
Patent number: 8445018Abstract: A pharmaceutical composition may include a coated particulate which may include at least one active pharmaceutical ingredient, particularly one susceptible to abuse by an individual. The coated particles may include a fat/wax and have improved controlled release and/or crush resistance. Method of making these coated particulate and dosage forms therewith are also described.Type: GrantFiled: March 12, 2008Date of Patent: May 21, 2013Assignee: Cima Labs Inc.Inventors: Walid A. Habib, Ehab Hamed, Manuel A. Vega Zepeda
-
Patent number: RE44459Abstract: The invention disclosed comprises a method for administering the antidiabetic drug glipizide to a patient in need of glipizide in need of antidiabetic therapy.Type: GrantFiled: March 2, 2012Date of Patent: August 27, 2013Assignee: Alza CorporationInventors: Anthony L. Kuczynski, Atul Devdatt Ayer, Patrick S. L. Wong